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ABSTRACT 
Objectives. We investigated whether catechol-O-methyltransferase (COMT) val158met polymorphism is 
associated with Eating Disorders (ED). 
Methods.  We conducted a systematic literature search of studies published until January 15,2017 and added 
data from the Italian ‘Biobanca Veneta per i Disturbi Alimentari’ biobank(BIO.VE.D.A.), performing a 
meta-analysis comparing COMT val158met genotype and allele frequencies in EDs, and AN or BN patients 
vs. controls. 
Results. Ten studies plus BIO.VE.D.A. (ED: n=920, controls: n=261 controls) with 3,541 ED patients 
(AN=2,388; BN=233) and 3,684 controls were included. There were no significant group differences in 
COMT val158met alleles and genotypes frequencies between patients and controls, for all EDs pooled 
together (range of odds ratios (ORs): 0.96-1.04, p-values: 0.46-0.97, I2=0%) and when analyzing separately 
patients with AN (ORs: 0.94-1.04, p-values: 0.31-0.61, I2=0%) or BN (ORs: 0.80-1.09, p-values: 0.28-0.64, 
I2=0-44%). 
Conclusions. Meta-analyzing data from 11 studies and 7,225 subjects, results show that COMT val158met 
polymorphism is not associated with EDs.  
Key words: polymorphism; anorexia nervosa; bulimia nervosa; Catechol- O-methyltransferase (COMT); 
val158met. 
  
  
INTRODUCTION 
Eating disorders (EDs) are severe psychiatric conditions characterized by a frequently disabling course and 
associated with high rates of comorbid psychopathology (Solmi, Veronese, et al., 2016), medical 
complications (Shuttleworth, Sharma, Lal, & Allan, 2016) (Solmi, Veronese, et al., 2016) and specific 
neuropsychological profiles (Treasure, Claudino, & Zucker) (Van den Eynde et al., 2011) .  
In the last decades, major advances have been made in the understanding of the neurobiology of EDs, with 
increasing knowledge in their pathophysiology (Veronese et al., 2015), genetic and epigenetic profiles 
(Zeynep Yilmaz, Hardaway, & Bulik, 2015), structural and functional brain alterations (Collantoni et al., 
2016) (Frank, 2015) and executive functioning impairment (Tenconi et al., 2010). Since dopamine is 
implicated in appetite regulation, eating and motor behaviors, emotional functioning and cognitive processes, 
the literature payed a great deal of attention to the possible role of this neurotransmitter in the 
pathophysiology of EDs.  
In particular, the dysregulation of fronto-striatal dopaminergic circuit has been considered a key factor in 
explaining the affective and cognitive alterations observed in anorexia nervosa (AN) and bulimia nervosa 
(BN) patients, since these neural pathways support self-regulatory capacities and reward-based learning 
(Berner & Marsh, 2014) (Kaye, Fudge, & Paulus, 2009). The role of genes implicated in dopaminergic 
prefrontal signaling and metabolism is therefore of particular interest in EDs, and has been investigated in 
several studies. 
Among the genes involved in dopamine prefrontal metabolism catechol-O-methyltransferase (COMT) 
appears to play a pivotal role in the modulation of fronto-striatal networks because it seems to have an 
important role in the modulation of neurocognitive functioning (Savitz, Solms, & Ramesar, 2006). The 
val158met is by far the most studied COMT polymorphism, as it modifies the thermal stability of the gene 
and thus its enzymatic activity, with complex consequences on cognitive operations influenced by DA 
signaling (Dickinson & Elvevåg, 2009).  
The relationship between DA tone in the prefrontal cortex and PFC-dependent cognitive performance is 
characterized by an inverted U-shape, which may be determined by differential effects of D1 and D2 
receptor binding (Bilder, Volavka, Lachman, & Grace, 2004). In particular, in the presence of the COMT 
Met allele DA levels in the prefrontal cortex increase and the resulting higher tonic D1 stimulation leads to 
beneficial effects on the stability of mental representations but at the cost of disadvantageous consequences 
on cognitive flexibility and working memory update abilities. Conversely, the COMT Val allele is associated 
with decreased DA concentrations and a low D1/high D2 state, which is associated with greater behavioral 
flexibility but also to higher impulsivity and risky decision making (Bilder et al., 2004).  
The study of the val158met COMT genotype in EDs is particularly interesting since the effects of the COMT 
enzyme are influenced by estrogen levels. Estrogens inhibit COMT mRNA expression, reducing the effect of 
the COMT enzyme activity and of the COMT genotype in women compared with men (Harrison & 
  
Tunbridge, 2008; Jacobs & D'Esposito, 2011). Since estrogen levels decrease greatly during starvation, 
underweight patients with anorexia nervosa represent a unique opportunity to study the interaction between 
estrogen levels and the COMT genotype.  
Several studies have investigated the relationship between AN and the COMT Val158Met polymorphism, 
while less data are available about BN. The most recent meta-analysis on COMT genotype and ED was 
based on literature searches conducted up to April 2011 (Brandys et al., 2012). However, since then 
additional studies have explored the potential association between EDs and COMT, and studies evaluating 
the relevance of COMT genotype in BN have not been meta-analyzed to date. Therefore, the aim of the 
present meta-analysis was to test whether COMT val158met polymorphism is associated with ED as a broad 
category, or specifically with AN or BN, summarizing all published evidence and adding novel data from the 
‘Biobanca Veneta per i Disturbi Alimentari’ biobank (BIO.VE.D.A) (Solmi, Gallicchio, et al., 2016).  
  
  
METHODS 
 
‘Biobanca Veneta per i Disturbi Alimentari’ (BIO.VE.D.A.) data 
The Bio.Ve.D.A. sample included 920 life-time cases of AN (n=562) and/or BN (n=358) according to DSM-
5 criteria (A.P.A., 2013), and 261 healthy controls (HC). These patients were recruited from five Eating 
Disorder Units of the Veneto region, Italy. The  Bio.Ve.D.A. project is funded by the Veneto Region and its 
main aim is to establish a genetic biobank for EDs. The following inclusion criteria were used: a life-time 
diagnosis of AN or BN according to DSM-5, age >14 years old, patients’ and parental (if less than 18 years 
old) informed consent. The study was approved by local hospital Ethics Committee. The following exclusion 
criteria were applied: organic comorbidity, or major psychiatric comorbidity (bipolar disorder, schizophrenia, 
major depressive disorder). All participants underwent saliva or blood sampling to collect DNA, which was 
extracted from 200μl of whole peripheral blood, using High Pure PCR Template Preparation Kit (Roche 
Diagnostics GmbH), or from 500μl of saliva with Oragene•DNA/saliva Kit (DNA Genotek Inc.) according to 
the manufacturer’s instructions.  
Procedures for genomic DNA extraction and for the COMT val158met polymorphism analysis have been 
described previously (Favaro et al., 2013).  
 
Meta-analysis 
Search strategy 
We conducted an electronic literature search in PubMed and SCOPUS from data base inception until January 
15th, 2017 for studies investigating COMT val158met genotype or alleles frequencies in EDs and a control 
group. The following search key was used: ("eating disorders"[MeSH Terms] OR ("eating"[All Fields] AND 
"disorders"[All Fields]) OR "eating disorders"[All Fields] OR "anorexia nervosa" OR "bulimia nervosa" OR 
"binge eating disorders") AND ("COMT"[All Fields] OR ("transferases"[MeSH Terms] OR 
"transferases"[All Fields] OR "transferase"[All Fields])). Equivalent search terms were used in Scopus.  
Reference lists of included articles and those relevant to the topic were hand-searched for identification of 
additional potentially relevant articles.   
 
Study selection 
Included were only peer-reviewed studies that i) included patients diagnosed with EDs according to DSM-5 
criteria; ii) reported COMT val158met genotype or allele frequencies in patients with EDs and a control 
group. Previous reviews and meta-analyses were full-text read to identify further studies. No language 
restrictions were applied.  
 
Data extraction and quality assessment 
Two authors (E.C. and D.G.) independently extracted data from selected studies into a standardized 
Microsoft Excel spreadsheet. Any disagreement was resolved by consensus with a third author (A.F.). The 
  
following information was extracted: (i) study population characteristics (e.g., sample size, demographics, 
diagnostic criteria and subtype of AN or BN, comorbidities, medications, anthropometric data); (ii) genotype 
or allele frequencies in patients and controls; (iii) quality indicators used for the STROBE assessment; and 
iv) Hardy-Weinberg equilibrium. Whenever studies had the same authors or affiliation or close publication 
year, we contacted authors to verify that data were not referring to the same sample. Whenever genotype or 
allele frequencies were not available, we contacted authors to ask for unpublished data at least twice. We ran 
the following comparisons within patients and within controls: i) Met/Met, Val/Val, and Val/Met genotype 
frequency differences between AN, BN, or EDs and HC; ii) Val and Met frequency differences between AN, 
BN, or EDs and HC.  
The Newcastle-Ottawa Scale (Wells, 2013) was used to  assess the quality of the included studies. 
 
Meta-analysis 
We meta-analyzed comparisons reported in at least two studies, in order to provide the maximum number of 
meta-analyzable outcomes.  
The meta-analysis was performed using Review Manager Version 5.3 for Windows (Review Manager 
(RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre). When combining 
studies, the random effects model (DerSimonian & Laird, 1986) was used to account for study heterogeneity. 
For dichotomous data, Odds Ratio (OR) with its 95% confidence interval (CI) was used. Heterogeneity was 
assessed with the Cochran Q and I2 statistics for each analysis, with I2 ≥50 indicating high heterogeneity 
(Higgins, Thompson, Deeks, & Altman, 2003).  Publication bias was assessed via visual inspection of funnel 
plots and Egger’s test (Egger, Davey Smith, Schneider, & Minder, 1997), with Comprehensive Meta-
Analysis (CMA).  In order to perform a sensitivity analysis and test for publication bias, we performed the 
trim and fill procedure to remove the most extreme small studies from the positive side of the funnel plot, 
and recalculated the effect size at each iteration, until the funnel plot was symmetric around the (new) effect 
size  (Duval & Tweedie, 2000) . 
We included BIO.VE.D.A. group data in the meta-analysis. Hardy-Weinberg equilibrium was tested in each 
study separately with both χ2 test and relative excess heterozygosity test (REH) (Ziegler, Van Steen, & 
Wellek, 2011). Finally, we tested the pooled REH from all included studies using a random effects model, 
which is a more appropriate tool than the χ2 test to test HWE in meta-analyses (Ziegler et al., 2011). 
 
  
  
RESULTS 
Search results (fig 1) 
We identified 354 studies through our electronic search, plus three additional references from the hand-
searched bibliography of relevant papers. After duplicate removal, the title and abstract of 312 papers were 
screened, and 292 were excluded. We assessed full text of 20 papers, and excluded ten additional references 
for different reasons specified in figure 1. Finally we included in the meta-analysis ten studies (Brandys et 
al., 2012; Dmitrzak-Weglarz M, 2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et al., 2001; 
Kim, Kim, & Kim, 2010; Mikolajczyk, Grzywacz, & Samochowiec, 2010; Peng et al., 2016; Pinheiro et al., 
2010; Z. Yilmaz, Kaplan, Zai, Levitan, & Kennedy, 2011), plus data from BIO.VE.D.A. 
 
Characteristics of included studies (table 1) 
The main features of the included studies are summarised in Table 1. Overall, we analyzed data from 3,541 
patients with EDs, and 3,684 controls not affected by any ED. Among the patients with EDs, 2,950 had a 
lifetime diagnosis of AN and 591 had a lifetime diagnosis of BN. The mean age was 23.4+5.9 years for ED 
patients, and 25.1+6,2for controls, the mean BMI was 17,03+ 2.7 Kg/m2 for patients (lowest mean BMI= 
15,6+.3 Kg/m2 based on 3 studies), and 20.2+1.5 Kg/m2 for controls. Seven studies only included patients 
with AN, one study included patients with BN, and three studies included both patients with AN and BN. 
Only one study reported data about life-time comorbidity, and one study reported information about 
concomitant medication treatment. In all studies, the COMT genotype was in Hardy-Weinberg Equilibrium, 
except one where such information was not reported. 
All studies compared patients with ED with non-affected healthy controls (sisters of patients in one study). 
Eight studies defined ED according to DSM-IV criteria (A.P.A., 2000), while BIO.VE.DA data defined ED 
according to DSM-5 (A.P.A., 2013), and one study each used ICD-10 (W.H.O., 1992) or EDE-Q(Fairburn & 
Beglin, 1994) criteria. 
 
Quality of included studies (table 1) 
Overall, the quality was high, with seven out of eleven studies meeting all quality criteria, three studies 
missing one, and one study missing two features instead (table 1).  
 
Meta-analysis (table 2, fig. 2) 
All results of the meta-analyses comparing patients with control groups are reported in Table 2.  
Considering EDs as a unique group (11 studies, 3541 patients and 3684 controls), neither COMT val158met 
allele nor genotype frequencies were different compared with controls (range of ORs: 0.96-1.04, p-values: 
0.46-0.97, I2=0%). The same was true in patients with AN (10 studies, 2950 patients, 3521 controls; range of 
ORs: 0.94-1.04, p-values: 0.31-0.61, I2=0%)), and in patients with BN (4 studies, 591 patients, 566 controls; 
range of ORs: 0.80-1.09, p-values: 0.28-0.64, I2=0-44%). 
  
Details of the comparative meta-analysis of Val allele distribution between patients with ED and controls is 
represented in figure 2.  
 
Publication  Bias 
Funnel plot visual inspection and Egger’s regression test showed the presence of publication bias (1.54, 
95%CI 0.46-2.51; p=0.003) for val/val genotype frequency comparative meta-analysis. However, the trim 
and fill procedure substantially confirmed our results, since looking for missing studies both to the left and to 
the right of the pooled effect size resulted in no difference in genotype frequency between the two groups. 
 
  
  
DISCUSSION  
Due to the importance of dopamine signaling for normal human behavior, the COMT val158met SNP is one 
of the most studied genetic variants in psychiatry (Schacht, 2016), and its role in influencing cognitive and 
executive performances has been assessed in several studies (Bruder et al., 2005; Goldberg et al., 2003; 
Scheggia, Sannino, Scattoni, & Papaleo, 2012). Given the importance of dopamine metabolism in limbic and 
executive-associative pathways, and the involvement of striatal and prefrontal circuits in the 
pathophysiology of EDs, we aimed to meta-analytically evaluate whether the COMT val158met genotype 
differed between ED patients and controls, as this would point to specific pathophysiologic underpinnings of 
EDs and could possibly point to novel treatment approaches.  
However, according to our analyses, there was no signal that COMT val158met polymorphisms are 
associated with AN or BN. Moreover, results were very homogenous and, although publication bias was 
present, results did not change after trim and fill procedure. Our results are consistent with those of the 
previous meta-analysis conducted by Brandys and colleagues, that rejected the hypothesis of an association 
between rs4680 and AN (Brandys et al., 2012). In addition, our meta-analysis also shows the absence of a 
significant association with BN, or ED as a combined category. BIO.VE.D.A. data, which represent the 
second largest database analyzed up to now considering AN diagnosis and the largest considering BN, were 
similarly consistent with the results of the other studies included in the meta-analysis. The fact that less 
studies investigated COMT polymorphisms in BN, compared with AN, is consistent with the more limited 
neurobiological characterization of BN and with a less homogeneous description of its neuropsychological 
functioning (Degortes, Tenconi, Santonastaso, & Favaro, 2016; Van den Eynde et al., 2011). Moreover, the 
absence of an association between COMT val158met genotype and ED mirrors similar results for the 
serotonin transporter 5-HTTLPR polymorphism, another monoamine modulating single polymorphism as 
previously reported (Rozenblat et al., 2017; Solmi, Gallicchio, et al., 2016). 
Despite the possible role of COMT val158met polymorphism in influencing executive functioning and 
prefrontal connectivity in AN (Favaro et al., 2013), this genetic variant does not seem to represent a risk 
factor for the development of EDs. Favaro et al hypothesized that, due to the estrogens effects, COMT 
effects on cognitive functioning might be observable only in acute underweight AN patients (Favaro et al., 
2013). From this perspective, it would be useful to explore the complex interaction between this genetic 
variant and estrogen levels not only with regards to the risk of developing an ED, but also as a factor 
involved in the maintenance of low BMI and lack of remission. Despite the current negative results, we 
suggest that the influence that COMT val158met genotype can exert on fronto-striatal functioning in ED and 
its consequences on clinical features, such as treatment response, should be further characterized by specific 
studies that investigate estrogen levels and executive functioning as possible mediators of outcome in EDs.  
The present study has both strengths and limitations that need to be taken into consideration when 
interpreting its results. First, one of the strengths is the inclusion of data from the BIO.VE.D.A. biobank, 
  
which provided the largest sample of patients affected by BN that has been investigated regarding the COMT 
val158met polymorphism and the second largest sample of patients diagnosed with AN. Second, the 
BIO.VE.D.A. sample was free from major psychiatric comorbidities (bipolar disorder, schizophrenia, major 
depressive disorder), removing the possibility of potential biases due to other major psychiatric disorders. 
Third, this is the first meta-analysis about the association between COMT val158met polymorphism and BN. 
The paucity of data about the role of this genetic variant in the etiology and in cognitive and executive 
features of BN points to the need of more studies that investigate these topics. Fourth, our meta-analysis 
added 4 studies, and 2356 subjects compared to the last meta-analysis that focused on AN only. Last but not 
least, our results showed low heterogeneity and lacked indication for publication bias, both when pooling 
EDs together and when analyzing AN and BN separately, which increases the confidence in our conclusions. 
Several limitations should also be mentioned. First, we acknowledge the lack of studies, which consider the 
presence of comorbid psychiatric disorders. Second, only few studies included non-Caucasian patients. Thus, 
our results may not be representative of specific ethnic groups. For example, although studies in a Chinese 
Han population (Peng et al, 2016) and in Korean subjects (Kim et al, 2010) also failed to find significant 
differences in COMT genotype between patients with EDs and HC, two studies (with an overlapping 
sample) conducted in an Israeli sample did report a significant association between rs4680 and AN. 
Nevertheless, overall, the results were consistent and homogenous. Third, frequently control groups were 
simply defined as not being affected by ED, without clear exclusion of other organic or psychiatric diseases. 
Finally, only the BIO.VE.D.A.  used the new diagnostic criteria using DSM-5, yet ED criteria do not vary 
greatly and this variation is unlikely to have influenced the results to a relevant degree.  
In conclusion, in this largest and most comprehensive meta-analysis to date, consistently no association was 
found between COMT val158met polymorphisms and ED, AN, or BN. Other genetic associations with ED, 
in general, and AN and BN, in particular, need to be investigated. 
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Figure 1. Flow-chart from literature search to study inclusion in meta-analysis. 
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Fig 2. Comparative meta-analysis of val/val genotype frequency in eating disorders (with anorexia nervosa 
and bulimia nervosa subgrouping) vs healthy controls*.  
Legend: *: controls have been reported twice for studies including AN and BN and actual total control number is 
5,684; AN: anorexia nervosa; BN: bulimia nervosa; ED: eating disders. 
Table 1. Characteristics of BIO.Ve.D.A. sample and included studies assessing catechol- O-methyltransferase val158met polymorphism in eating disorders vs controls. 
Study/ Country ED 
diagnostic 
criteria 
HC 
Group  
N  
AN/ 
BN 
N HC 
group 
Age 
AN/BN 
Age 
HC 
BMI  
AN/BN 
(Kg/ m2) 
BMI 
HC (Kg/ 
m2) 
Lowest 
BMI 
ever 
AN/BN 
Lowes
t BMI 
ever 
HC 
Onset 
Age 
(yrs) 
Measure
ment 
Method  
Lifetime 
co-
morbidit
y 
Medi-
cations 
Personality 
or 
Symptom 
Scale or 
other 
Clinical 
Data 
Genotype 
in Hardy-
Weinberg 
Equilibriu
m 
NOS 
BIO.Ve.D.A. 
group. 
2016 
Italy 
DSM-5 Non 
affected 
controls 
AN 
562, 
BN 
358 
261 AN 
24.9+9,  
BN 
26.5+8.
4 
- AN 
15.5+1.6
, 
BN 
22.1+4.1 
21.3+2.4 - - AN 
18.3+5.9, 
BN 
17.9+5.1 
Saliva/bl
ood, 
PCR 
- - - 
  
Yes 9 
Gabrovsek et al. 
2004 
Multicentric: 
Italy (Florence 
and Milan), 
Spain, UK, 
Austria, 
Germany, 
Slovenia 
DSM IV Non 
affected 
controls 
AN 
266 
(251 
F, 5 
M) 
418  - - ED: 
14.5+0.3 
 
 
- AN-BP: 
16.1+3.5 
AN-R: 
14.3+2.1 
- ED: 
18.3+4.3 
 
AN-BP: 
17.5+4.6 
AN-R: 
17.4+4.6 
Cheek 
swabs, 
blood, 
PCR-
RFLP, 
ARMS 
assay  
- - - 
  
Yes 8 
Mikolajczyk et 
al. 2010 
Poland 
 
ICD 10 Non 
affected 
controls 
AN 
61 
BN 
42 
108 ED: 
22.45+
3.85 
AN: 
22.07+
3.76 
BN: 
23.00+
3.95 
22.85
+3.7
1 
ED: 
16.84+3.
56 
AN: 
15.05+2.
54 
BN: 
19.41+3.
27 
20.65+1.
25 
- - - Blood, 
PCR-
RFLP 
- - EDI 
TCI 
Yes 9 
Kim et al. 2010 
Korea 
EDE-Q Non 
affected 
controls 
AN 
40 
BN 
28 
34 AN 
22.78+
7.23 
BN 
23.00+
3.21 
22.65
+3.5
7 
AN 
16.67+2.
60 
BN 
20.66+2.
65 
21.52+1.
68 
AN 
14.60+1.
51 
BN 
18.12+2.
19 
20.19+
1.52 
AN 
18.55+4.
59 
BN 
20.07+2.
99 
PCR, 
blood 
 
- 19 AN: 
SSRI 
15 BN: 
SSRI 
WAIS-IQ; 
TMT (Part 
A+PartB) 
VST; FTT; 
BDI; STAI; 
K-MOCI 
Yes 9 
Legend: *: study provided data from two samples; AN: anorexia nervosa; BDI: Beck Depression Inventory; BIO.Ve.D.A.: biobanca veneta per i disturbi del comportamento alimentare – 
Veneto region biobank for eating disorders; BMI: body mass index; BN: bulimia nervosa; DSM: diagnostic and statistical manual; EDE: Eating Disorders Examination Interview; EDI: 
Eating Disorders Inventory; FTT: Finger Tapping Test; HC = healthy control; ICD: international classification of diseases; K-MOCI: Korean Version of Maudsley Obsessive Compulsive 
Inventory; NOS: Newcastle-Ottawa Scale; SCID-1: Structural Clinical Interview for DMS-IV for Axis I disorders; SCL-90R: Symptom Checklist 90 Revised; SSRI: selective serotonin 
reuptake inhibitors; STAI: State and Trait Anxiety Inventory; TCI: Temperament and Character Inventory; TMT: Trail Making Test; VST: Visual Span Test; WAIS-IQ: Wechsler Adult 
Intelligent Scale; WURS: Wender  Utah Rating Scale. 
Yilmaz et al. 
2011 
Canada 
DSM IV Non 
affected 
controls 
BN 
163 
163 - - - - - - - Blood 
High-salt 
Method 
ADHD - SCID-1 
EDE 12 
WURS 
Yes 9 
Brandys et al. 
2012* 
Netherland 
DSM IV 
 
Non 
affected 
controls 
AN 
480 
1475 25.6+-
7.1 
23.4
+12.
1 
15.3+2.3 22.6+14.
1 
- - - Mass 
Spectro
metry 
- - - Yes 9 
Gervasini et al. 
2013 
Spain 
DSM IV Non 
affected 
controls 
AN 
78 
186 26+7.4 22.18
+6.1
3 
17.60+2.
33 
22.13+3.
45 
- - 17.16+5.
11 
Blood - - EDI-2 
SCL-90R 
Yes 9 
Peng et al., 
2016 
China 
DSM IV Non 
affected 
controls 
AN 
249 
189 19.09+
4.72 
22.76
+3.3
0 
- - - - - Blood - - - Yes 7 
Pinheiro et al., 
2010 
Multicentric, 
primarily 
European 
DSM IV Non 
affected 
controls 
AN 
1079 
677 27.1+8.
8 
26.3
+8.3 
14.7+2.5
4 
22.1+1.8 - - - - - - - Yes 9 
Dmitrzak-
Weglarz et al., 
2005 
Poland 
DSM IV Non 
affected 
controls 
AN 
91 
135 18.5 
+3.2 
34.9
+10 
- - - - - - - - - Yes 8 
Karwautz et al., 
2001 
UK 
DSM IV Non 
affected 
controls 
(control 
were 
sisters of 
the 
probabn
ds) 
AN 
44 
38 - 27.4
+ 2.2 
- 22.4 + 
3.8 
13.1+2.2 - 15.3+3.2 - - - - - 8 
11 studies DSM-IV: 
n=8, DSM-
5=1,  
ICD-10: 
n=1 EDE-
Q: n=1 
Non 
affected 
controls 
3541(
AN=
2950; 
BN=
591) 
3684 23.4+5.
9; AN: 
23+6.2;
BN 
24.2 + 
5.2 
 
25.1
+6,2 
17,03+ 
2.7; AN: 
15,9+4,9
; BN: 
20,7+3,3 
22,1+5,8 15,61+.3 
AN:14.5
+ 10.2; 
BN:18.1
+2.2 
20.2+-
1.5 
17.8+4,5
; 
AN:17.4
+4.4 ; 
BN: 
19+4 
 Blood: 
n=7; 
NA=3; 
Mass 
Spectro
metry: 
n=1;  
ADHD: 
n= 1 
N=1 
(19 
AN: 
SSRI 
15 BN: 
SSRI) 
Yes: n=4 
No: n=7 
Yes: n=10, 
NR: n=1 
8.5+
0.7 
Table 2: Results of the meta-analysis comparing COMT val158met in patients with eating disorders, anorexia nervosa and bulimia nervosa vs. comtrols 
Table 2. Comparative meta-analysis of catechol-O-methyltransferase (COMT)  val158met polymorphism frequency in eating disorders vs healthy controls. 
Comparison Number 
of studies 
Studies Participants 
(patient vs. 
HC) or alleles 
Statistical 
Method 
Effect estimate Heterogeneity 
(I2) 
       
EDs * (AN and BN) 
vs. controls 
      
Val allele 11 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et 
al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010; Yilmaz et al., 2011 
7082 vs 8174 
 
Odds ratio 
(M-H, 
random, 95% 
CI) 
0.99 [0.92, 1.06]; 
P=0.67 
- 
0% 
Met allele 11 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et 
al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010; Yilmaz et al., 2011 
7082 vs 8174 
 
 
Odds ratio 
(M-H, 
random, 95% 
CI) 
1.02 [0.95, 1.09]; 
P=0.58 
 
0% 
Val/Val 11 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et 
al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010; Yilmaz et al., 2011 
3541 vs 4087 Odds ratio 
(M-H, 
random, 95% 
CI) 
0.96 [0.86, 1.07]; 
P=0.46 
 
10% 
Val/Met 11 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et 
al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010; Yilmaz et al., 2011 
3541 vs 4087 Odds ratio 
(M-H, 
random, 95% 
CI) 
1.04 [0.94, 1.14]; 
P=0.48  
0% 
Met/Met 11 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et 
al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010; Yilmaz et al., 2011 
3541 vs 4087 Odds ratio 
(M-H, 
random, 95% 
CI) 
1.00 [0.90, 1.12]; 
P=0.97 
 
0% 
AN Vs. controls       
Val allele 10 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et 
al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010 
5900 vs 7042 
 
Odds ratio 
(M-H, 
random, 95% 
CI) 
0.97 [0.90, 1.04]; 
P=0.36 
 
0% 
Met allele 10 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 5900 vs 7042 Odds ratio 1.04 [0.96, 1.12]; 0% 
Table 2: Results of the meta-analysis comparing COMT val158met in patients with eating disorders, anorexia nervosa and bulimia nervosa vs. comtrols 
Comparison Number 
of studies 
Studies Participants 
(patient vs. 
HC) or alleles 
Statistical 
Method 
Effect estimate Heterogeneity 
(I2) 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et 
al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010 
 (M-H, 
random, 95% 
CI) 
P=0.32 
 
Val/Val 10 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et 
al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010 
2950 vs 3521 Odds ratio 
(M-H, 
random, 95% 
CI) 
0.94 [0.83, 1.06]; 
P=0.31 
 
0% 
Val/Met 10 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013; Karwautz et 
al., 2001; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010 
2950 vs 3521 Odds ratio 
(M-H, 
random, 95% 
CI) 
1.03 [0.93, 1.14]; 
P=0.61 
 
0% 
Met/Met 10 BIO.VE.D.A. group; Brandys et al., 2011; Dmitrzak-Weglarz et al., 
2005; Gabrovsek et al., 2004; Gervasini et al., 2013 Karwautz et 
al., 2001;; Kim et al., 2010; Mikolajczyk et al., 2010; Peng et al., 
2016; Pinheiro et al., 2010 
2950 vs 3521 Odds ratio 
(M-H, 
random, 95% 
CI) 
1.03 [0.91, 1.17] 
P=0.61 
 
0% 
BN vs. Controls       
Val allele 4 BIO.VE.D.A. group ; Kim et al., 2010; Mikolajczyk et al., 2010; 
Yilmaz et al., 2011 
1182 vs 1132 
 
Odds ratio 
(M-H, 
random, 95% 
CI) 
1.09 [0.92, 1.29]; 
P=0.32 
 
27% 
Met allele 4 BIO.VE.D.A. group ; Kim et al., 2010; Mikolajczyk et al., 2010; 
Yilmaz et al., 2011 
1182 vs 1132 
 
Odds ratio 
(M-H, 
random, 95% 
CI) 
0.93 [0.79, 1.10]; 
P=0.39 
 
0% 
Val/Val 4 BIO.VE.D.A. group ; Kim et al., 2010; Mikolajczyk et al., 2010; 
Yilmaz et al., 2011 
591 vs 566 
 
Odds ratio 
(M-H, 
random, 95% 
CI) 
1.07 [0.81, 1.40]; 
P=0.64 
 
44% 
Val/Met 4 BIO.VE.D.A. group ; Kim et al., 2010; Mikolajczyk et al., 2010; 
Yilmaz et al., 2011 
591 vs 566 
 
Odds ratio 
(M-H, 
1.07 [0.85, 1.36]; 
P=0.55 
0% 
Table 2: Results of the meta-analysis comparing COMT val158met in patients with eating disorders, anorexia nervosa and bulimia nervosa vs. comtrols 
Comparison Number 
of studies 
Studies Participants 
(patient vs. 
HC) or alleles 
Statistical 
Method 
Effect estimate Heterogeneity 
(I2) 
random, 95% 
CI) 
 
Met/Met 4 BIO.VE.D.A. group ; Kim et al., 2010; Mikolajczyk et al., 2010; 
Yilmaz et al., 2011 
591 vs 566 
 
 
Odds ratio 
(M-H, 
random, 95% 
CI) 
0.80 [0.53, 1.21]; 
P=0.28 
 
0% 
 
Legend: *: in EDs analyses HCs have been computed twice for studies including both AN and BN. Actual maximum total control number is 5,684; AN: anorexia nervosa; BN: 
bulimia nervosa; ED: eating disorders; HC: healthy controls. 
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